AI assistant
Vivesto — AGM Information 2011
Sep 30, 2011
3124_rns_2011-09-30_017d2191-9940-48a4-bacc-f8bf5afe20b3.pdf
AGM Information
Open in viewerOpens in your device viewer
2011-09-30
Communiqu€from Annual General Meeting 2011
Oasmia Pharmaceutical AB (publ.) VAT no SE556332 -667601 held itsAnnual General Meeting for the fiscal year 2010/2011 on Friday, September 30, 2011 and the following resolutions were made. Fordetailed information about the content of the resolutions, see the complete notice for Annual General Meeting available at the Oasmia website together with the complete proposals for the resolut ions below.
Establishment of Balance Sheet and Income Statement
The Annual General Meeting established the Balance Sheet, Income Statement, Consolidated Accounts and Financial r eport. It was resolved thatshare premium reserve SEK 413 374526, accumulatedprofit of SEK-63 029528, and profit for the year SEK-65 998 058,in total SEK 284346940, shall be brought forward.
The Board of Directors
The Annual General Meeting discharged the Board of Directors and the Chief Executive Officer from liability for the fiscal year 2010/2011. TheAGM made a resolution thathe Board shall consist of sixregular members without deputies. The AGM re-elected the Board members Bo Cederstrand and Julian Aleksov and newly elected Joel Citron, Martin Nicklasson , Jan Lundberg and Prof. Dr.Horst Domdey. Joel Citron was elected as Chairman of the Board.
Remuneration to the Board and auditors
The AGM established that a member of the Board not employed by the company shall receive remuneration amounting to SEK 250000. Remuneration to a Board member may, by special agreement with Oasmia Pharmaceutical AB, be invoiced by a company wholly -owned by the Board member. In that case, the invoiced fee will beincreased by the amount of social security contributions and VAT. Remuneration to the auditors shall be paid according to bill.
Guidelines for remuneration to senior managers The AGM approved the guidelines for remuneration to senior managers proposed by the Board.
Nomination committee
TheAGMapproved the proposal concerning criteria for the selection of a nomination committee for the AGM 2012.
Revision of the Articles of Association
TheAGM approved thepresentedproposal concerning revision of the Articles of Association wth respect to new regulations in the Companies Act concerning Notice of General Meeting.
Authorization for the Board to make decisions on issue ofnew shares and convertible debt instruments
TheAGMmade a resolution to, in accordance with the proposal by the Board, authorize the Board to make, at one or more occasions, with or without deviation from shareholders€ preferential rights, new share issues for cash payme nt and/or in kind or offset, or otherwise in accordance with cp t 13 • 7 of the Companies Act , and new issues of convertibles for cash payment and/or in kind or offset, or otherwise in accordance with cpt 15 • 5 of the Companies Act . The total number of shares issued supported by the authorization may not exceed 15 000000. The total number of convertibles issued supported by the authorization may not exceed more convertibles than enables conversion to 15000000 shares.
For more information, please contac t:
Julian Aleksov Chief Executive Officer Oasmia Pharmaceutical AB Telephone: +46 (0) 18 50 54 40 E-mail: [email protected]
For more information, please contact: Maria Lund'n, Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: [email protected]mPhone: +46 (0) 18 50 54 40. German co ntacts: Dr. Sƒnke Knop, Peggy Kropmanns, edicto GmbH, Frankfurt,Germany. E-Mail: [email protected]e, Phone : +49 (0) 69 90 55 05 51. Information is also available at www.nasdaqomxnordic.comwww.boerse-frankfurt.de
€Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submittedfor publicationat 16.30CET onSeptember 30, 2011.•